“ In2018,weledGlobalBlood
Therapeutics’equityoffering,
helpingthecompanytoadvance
thedevelopmentofitslead
medicineforsicklecell.”
MichaelBrock
ManagingDirector
WellsFargoSecurities“ Wells Fargo has belief in what we’re
doing – trying to change sickle cell
from a disease that kills you to
one you can live with. We hope to
make our fi rst medicine, voxelotor,
available to patients next year.”
Dr. Ted Love
CEO
Global Blood Therapeutics
Learn more about Wells Fargo’s Healthcare Banking
wellsfargo.com/healthcarebanking